Media Orientation to Improve Childhood Vaccine Uptake and Address Parent and Caregivers Vaccine-related Anxiety: A Pilot Study
NCT07510230 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2026-04-03
Summary
Vaccine hesitancy-defined as delayed acceptance or refusal of vaccines despite availability-remains a significant barrier to childhood immunisation uptake in Nigeria, a country with high zero-dose unvaccinated children. Several factors limit vaccine uptake, including poor awareness, misinformation, fear, anxiety and a perceived sense of conspiracy. Yet, a gap exists to address this urgent problem. The proposed study seeks to pilot the feasibility and acceptability of a novel co-produced media campaign intervention called ASSURed awareness campaign to encourage childhood vaccine uptakE (ASSURE) with parent-caregivers who are not or partially up to date with their child's vaccination. The ASSURE intervention is designed to encourage vaccine uptake and access, reduce vaccine hesitancy whilst addressing vaccine-related anxiety. The ASSURE intervention is low-intensity, lasting approximately 3-5-minute designed to raise awareness of the need for vaccination uptake and its implications for children, including their development and well-being whist addressing vaccine related anxiety and fears. The proposed study is also to pilot and test the instrument to determine effectiveness and cost effectiveness including the mechanism on why the intervention might potentially work.
Conditions
- Anxiety
- Vaccination Hesitancy
- Vaccination Promotion
- Vaccine Decision Making
- Immunisation Anxiety Related Reaction
Interventions
- BEHAVIORAL
-
ASSURed awareness campaign to encourage childhood vaccine uptakE (ASSURE) intervention
The media intervention is a low-intensity intervention lasting 3-5 minutes. The intervention is designed to promote awareness on the risk of vaccine hesitancy, its implication on the child wellbeing and health outcomes, the benefits of vaccination and immunisation and avenues or mediums for accessing childhood immunisation. The media intervention will also address anxiety associated with childhood vaccination and avenues for support. The recorded message introduction will commence with a welcome address on the topic, and this is followed by the core message and a closing remark. The core message is composed of three key ambits: 1) emphasising what is meant by vaccine hesitancy, risk of non-childhood immunisation, including the benefit of vaccination (ii) the need to vaccinate and stop societal stigmatising behaviour (iii) Avenues for accessing childhood immunisation and vaccination.
- BEHAVIORAL
-
Intervention as usual
Existing information provided by primary health care centre around childhood vaccination.
Sponsors & Collaborators
-
Jos University Teaching Hospital
collaborator OTHER -
University of Manchester
collaborator OTHER -
Teesside University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-04-20
- Primary Completion
- 2027-02-08
- Completion
- 2027-02-08
More Related Trials
-
Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)
NCT00496093 ·Status: COMPLETED ·Phase: PHASE3
-
Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
NCT02146365 ·Status: COMPLETED
-
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects
NCT01531322 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
NCT07023081 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
NCT03489018 ·Status: COMPLETED ·Phase: PHASE4
-
PCV10 Reactogenicity and Immunogenicity Study - Malindi
NCT01028326 ·Status: UNKNOWN ·Phase: PHASE4
-
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
NCT04551248 ·Status: UNKNOWN
-
A Safety Study For Prevenar 13 Among Chinese Children
NCT03656939 ·Status: COMPLETED
-
Safety and Local Tolerability of Prevenar in Indian Children
NCT00488800 ·Status: COMPLETED
-
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria
NCT01153893 ·Status: COMPLETED ·Phase: PHASE3
-
PRomoting Older Adults' Pneumococcal Vaccination Through Education and Learning
NCT06234683 ·Status: COMPLETED ·Phase: NA
-
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT06838000 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
NCT00836641 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso
NCT01577771 ·Status: COMPLETED ·Phase: PHASE4
-
Phase I Clinical Trial of a Candidate PCV13 in Healthy People
NCT05602480 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
NCT02062281 ·Status: COMPLETED ·Phase: PHASE4
-
PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae
NCT02133469 ·Status: COMPLETED ·Phase: NA
-
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
NCT04278248 ·Status: COMPLETED ·Phase: PHASE3
-
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT07035054 ·Status: COMPLETED ·Phase: PHASE2
-
Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
NCT04275284 ·Status: COMPLETED
-
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
NCT07348692 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
NCT06622109 ·Status: ACTIVE_NOT_RECRUITING
-
Booster and Catch-up Vaccination With Vaccine GSK1024850A
NCT01030822 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
NCT06531538 ·Status: COMPLETED ·Phase: PHASE2